Evaluating the risk of hepatocellular carcinoma in patients with prominently elevated liver stiffness measurements by FibroScan: a multicentre study

Adler, M; Larocca, Licia; Trovato, Francesca M.; Marcinkowski, H.; Pasha, Y A Zahed; Taylor-Robinson, Simon D

doi:10.1016/j.hpb.2016.05.005

Cited by 20 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, in the study of Adler et al [17] which was a retrospective observational study shows an association between liver stiffness measurements at the upper extreme and increasing HCC risk in patients with cirrhosis. LSM by Fibroscan allows stratification of HCC risk in a noninvasive and reliable way [26][27][28][29][30].…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Role of Fibroscan for early detection of hepatocellular carcinoma (HCC) in hepatitis C cirrhotic patients

Ebrahim

Shehata

Abou-Saif

et al. 2020

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

Background: Liver cancer (HCC) ranks as the fifth most prevalent cancer worldwide and is ranked third as a common cause of death due to cancer. The benefit of Fibroscan in assessing the risk of developing liver cancer that was evaluated in this work was not fully demonstrated. The aim of this work was to study the role and clinical significance of Fibroscan for early detection of liver cancer in hepatitis C patients with cirrhosis. Results: As regards binary logistic regression for predictors of HCC, it was found that Child C, AST, Fibroscan, and AFP were predictors for developing HCC. Liver stiffness values were significantly high in all groups, and the specific cutoff value for hepatocellular carcinoma detection was above 24 kPa in hepatitis C virus patients. Therefore, liver stiffness of more than 24 kPa can be considered as an independent risk factor for the development of liver cancer in HCV patients. Conclusion: Liver stiffness of more than 24 kPa was an independent risk factor for developing new liver cancer in HCV patients.

show abstract

Section: Discussionmentioning

confidence: 96%

“…Recently, the risk of liver cancer was assessed based on liver stiffness measured by Fibroscan among the European population [17]; however, in most reports, the risk of liver cancer has been indirectly assessed based on the value of cirrhosis as measured by Fibroscan; however, HCCassociated liver stiffness was not directly assessed [18].…”

Section: Introductionmentioning

confidence: 99%

Role of Fibroscan for early detection of hepatocellular carcinoma (HCC) in hepatitis C cirrhotic patients

Ebrahim

Shehata

Abou-Saif

et al. 2020

Egypt J Radiol Nucl Med

View full text Add to dashboard Cite

show abstract

“…The lower prediction performance and threshold in this study might be explained by the enrollment of decompensated cirrhosis patients and LS values determined at CVR in which confounding factors including inflammation were minimized. Our proposed cutoff was similar to the value of 20 kPa where in cirrhosis patients with the higher LS values, the greater risk was in HCC development . While achievement of the lowest LS is better, the thresholds of 21.5 and 11.6 kPa for cirrhosis patients with extreme high value and compensated advanced liver disease, respectively, might be the practical goal of potent NA therapy in clinical practice to reduce the risk of HCC development .…”

Section: Discussionmentioning

confidence: 63%

Liver stiffness measurement at complete virological response in hepatoma prediction for HBV‐related cirrhosis patient with potent antiviral agent

Wang

Chen

et al. 2019

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) development is ameliorated with nucleos(t)ide agent (NA) therapy for hepatitis B virus (HBV)-related cirrhosis patients. This study investigates whether liver stiffness (LS) measurement at complete virological response (CVR) was useful in predicting HCC development. Between July 2006 and August 2016, HBVrelated cirrhosis patients with potent NA (entecavir/tenofovir) with the first LS measurement during CVR and with serial LS were enrolled. Patients developing HCC 6 months after potent NA or before the first LS measurement were excluded. Three hundred and seventy-one patients were enrolled. The median follow-up was 5.6 and 3.8 years from potent NA treatment and the first LS measurement respectively. Twenty-seven patients developed HCC. The 1-, 3-, 5-and 7-year cumulated incidences of HCC occurrencewere 0%, 2.8%, 5.8% and 9%, respectively. In addition to age > 57 years, LS > =21.5 kPa (HR: 3.86, 95%CI: 1.67-8.94) was an independent factor associated with HCC occurrence in multivariate analysis. However, the magnitude of change in LS was not associated with HCC development. For the first LS in HCC prediction, the performance was 0.636. There were two to thirteen LS measurements during CVR. The change in LS was classified into four patterns stratified by the first and serial LS. Compared with those with serial LS < 21.5 kPa, patients with LS > =21.5 kPa tend to have higher HCC occurrence (P = .062). In summary, LS at CVR was an independent factor associated with HCC development for HBV-related cirrhosis patients with potent NA. However, LS was not satisfactory in the prediction performance of HCC development. K E Y W O R D S hepatic cirrhosis, hepatitis B virus, hepatocellular carcinoma, liver stiffness, nucleos(t)ide agent

show abstract

“…Therefore, several useful non-invasive methods for assessing liver fibrosis have been proposed and confirmed, such as FibroScan [27]. LSM by FibroScan had been recognized as an accurate method for assessing the stage of liver fibrosis in patients with chronic HBV infection [28], indicating values increasing as the liver disease progresses, and relating to HCC patients with cirrhotic background [29]. Jung et al [17] confirmed the high-preoperative LSM was associated with future science group www.futuremedicine.com significantly greater risk for recurrence of HCC, suggesting LSM can be a useful predictor of recurrence after curative resection of HCC.…”

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Preoperative Liver Stiffness Measurements in Primary HBV-Positive Hepatocellular Carcinoma

Chen

Zhang

et al. 2017

Future Oncol.

View full text Add to dashboard Cite

Aim: To analyze clinical significance of preoperative liver stiffness measurement (LSM) by FibroScan in postcurative resection hepatitis B virus (HBV) related hepatocellular carcinoma (HCC). Patients & methods:A total of 263 patients underwent preoperative LSM and curative operation for primary HBV-positive HCC were enrolled. The correlation between preoperative LSM and survival was analyzed. Results: All patients were stratified into two groups using the optimal cut-off value (13.2 kPa) of LSM using the receiveroperating characteristic. Patients with an LSM ≥13.2 kPa had poorer overall survival (median, 61.3 vs 48.2 months, hazard ratio: 0.15; p = 0.009) and recurrence-free survival (median, 60.4 vs 47.0 months; hazard ratio: 0.32; p = 0.011) than patients with an LSM <13.2 kPa and LSM also have been confirmed as independent predictor for survival for HCC. Discussion: This could potentially guide patient stratification and individualized treatment. Conclusion: Preoperative LSM can be considered as an independent prognostic factor for HBV-positive HCC after curative resection.

show abstract

Evaluating the risk of hepatocellular carcinoma in patients with prominently elevated liver stiffness measurements by FibroScan: a multicentre study

Abstract: This study shows an association between LSM at the upper extreme and HCC risk. Physicians may find this beneficial as a non-invasive dynamic approach to assessing HCC risk in cirrhosis patients.

Cited by 20 publications

References 32 publications

Role of Fibroscan for early detection of hepatocellular carcinoma (HCC) in hepatitis C cirrhotic patients

Role of Fibroscan for early detection of hepatocellular carcinoma (HCC) in hepatitis C cirrhotic patients

Liver stiffness measurement at complete virological response in hepatoma prediction for HBV‐related cirrhosis patient with potent antiviral agent

Clinical Significance of Preoperative Liver Stiffness Measurements in Primary HBV-Positive Hepatocellular Carcinoma

Contact Info

Product

Resources

About